Introduction: Since the emerging Delta variant of COVID-19 in 2021, the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) have encouraged world citizens to get booster vaccination. Booster vaccination has been used worldwide to prevent severe COVID-19. Healthcare providers were given the priority to be vaccinated, and the Moderna vaccine was given as chosen booster vaccination. Cutaneous side effect related to the Moderna vaccine has been reported in Public Secondary Hospital in both two cities in Indonesia, Jakarta and Tangerang. Material & Methods: The observation for this report took place from August until September 2021. All the patients gave their informed consent to participate in this case report and explicit consent to use their clinical photos. We collected data on 357 cases for 2 months in Dr. Suyoto Hospital (Jakarta) dan Dr. Sitanala Hospital (Tangerang). Results: The total number of healthcare workers who got the booster vaccine was 1370, and the number of experienced Moderna Arm was 350 cases: 321 cases with edema, urtica, and erythematous rash, and 29 cases with ecchymosis in Suyoto Hospital while in Sitanala Hospital 7 cases of urtica & erythematous rash. Conclusion: There were side effects after the Moderna injection, and it was important to inform the recipient about those effects.
Background: Platelet Rich Plasma (PRP) is an autologous concentration of human platelets contained in a small volume of plasma, has been proposed as a potential adjuvant therapy to Female Pattern Hair Loss (FPHL). Despite the widespread use of PRP in numerous fields of medicine, there have been few studies that investigated the clinical efficacy of PRP in FPHL. Methods: Fourteen female patients, age ranged from 20-45 years, diagnosed with female pattern hair loss were enrolled in this single-blinded randomized placebo-controlled study. Fourteen patients were divided randomly into two groups: Group 1 were injected with PRP using insulin syringe and group 2 were injected with normal saline as placebo. All patients were followed at 3 and 6 months after the last treatment sessions. Of the total subjects enrolled, on ten subjects completed the study. In total, 7 (70%) individuals received PRP and 3 (30%) received placebo. During all the treatment sessions, there were no severe adverse events reported. The study yielded investigator, subject and photographic assessments. Results: On the basis of the independent-blinded investigator assessment of change in the patient’s scalp hair growth from baseline, treatment in PRP group demonstrated as scale 1 improvement in 5 subjects (26-50%) and scale 2 improvement in 2 subjects (51-75%) at the final visit as compared to baseline (Fig. 1,2). In contrast, in the placebo group were rated as scale 0 improvement (0-25%). Conclusion: PRP injection for FPHL is a simple, cost-effective and feasible treatment option with good safety profile. However more randomized and multicentric trials with a large number of patients will be required to prove the validity of these results, to obtain these answers and to get more robust statistical results.
Khairani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.